Artur Katz

Progression-free survival and time to progression as primary end points in advanced breast cancer: often used, sometimes loosely defined

Everardo D. Saad, Artur Katz · Annals of Oncology · 2008 · 111 citations

Progression-free Survival, Advanced Breast Cancer, Breast Oncology +8

Pretreatment CA 19-9 Level as a Prognostic Factor in Patients with Advanced Pancreatic Cancer Treated with Gemcitabine

Everardo D. Saad, Marcel Cerqueira César Machado, Dalia Wajsbrot et al. · International Journal of Gastrointestinal Cancer · 2002 · 109 citations

Sequential liquid biopsies reveal dynamic alterations of EGFR driver mutations and indicate EGFR amplification as a new mechanism of resistance to osimertinib in NSCLC

Franciele Hinterholz Knebel, Fabiana Bettoni, Andrea Kazumi Shimada et al. · Lung Cancer · 2017 · 73 citations

Egfr Driver Mutations, Sclerostin, Bone Morphogenic Protein +7

Impressive response to dabrafenib, trametinib, and osimertinib in a metastatic EGFR-mutant/BRAF V600E lung adenocarcinoma patient

Maurício Fernando Silva Almeida Ribeiro, Franciele Hinterholz Knebel, Fabiana Bettoni et al. · npj Precision Oncology · 2021 · 41 citations · Full text

A prospective randomized evaluation of three schedules of mesna administration in patients receiving an ifosfamide-containing chemotherapy regimen: sustained efficiency and simplified administration

Artur Katz, Sidnei Epelman, Agnaldo Anelli et al. · Journal of Cancer Research and Clinical Oncology · 1995 · 31 citations · Full text

Ifosfamide-containing Chemotherapy Regimen, Medicine, Metronomic Therapy +8